Purple Biotech (NASDAQ:PPBT) released promising preclinical data on Monday for its lead therapeutic candidate, IM1240, demonstrating consistent anti-tumor activity across seven distinct patient-derived tumor samples.
The findings, which focus on the candidate’s ability to reshape the tumor microenvironment, suggest a potent new pathway for treating solid tumors.
IM1240 is a conditionally activated, "capped" tri-specific antibody designed to target CD3, 5T4, and NKG2A.
The "capping" technology is engineered to ensure the drug remains inactive in systemic circulation, only becoming fully functional upon reaching the tumor site.
This localized activation is intended to maximize efficacy while minimizing off-target toxicities.
According to the company, the inclusion of the NKG2A arm significantly enhanced the antibody's overall activity by bridging the innate and adaptive immune systems.
In models of non-small cell lung cancer (NSCLC), researchers observed that IM1240 induced the formation of mature tertiary lymphoid structures (TLS).
These structures act as "immune factories" within the tumor, facilitating a more aggressive and sustained attack by the body's natural defenses.
The data specifically showed a marked increase in the infiltration of T-cells and Natural Killer (NK) cells.
By simultaneously engaging T-cells (via CD3), targeting tumor-associated antigens (via 5T4), and blocking inhibitory checkpoints (via NKG2A), IM1240 represents a multi-pronged approach to immunotherapy.
Management noted that the ability to drive mature TLS formation is a particularly encouraging indicator of the drug's potential to turn "cold" tumors "hot," potentially improving outcomes in patients who have traditionally been resistant to standard checkpoint inhibitors.